LENZ Therapeutics, Inc. (NASDAQ:LENZ) Given Average Recommendation of “Buy” by Brokerages

Shares of LENZ Therapeutics, Inc. (NASDAQ:LENZ) have received an average recommendation of “Buy” from the seven ratings firms that are currently covering the stock, MarketBeat.com reports. Six analysts have rated the stock with a buy rating and one has issued a strong buy rating on the company. The average 1-year target price among analysts that have issued a report on the stock in the last year is $35.40.

Separately, HC Wainwright reissued a “buy” rating and issued a $38.00 target price on shares of LENZ Therapeutics in a research report on Thursday, November 7th.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of the business. Mirae Asset Global Investments Co. Ltd. purchased a new position in LENZ Therapeutics in the 4th quarter worth approximately $29,000. SG Americas Securities LLC purchased a new position in shares of LENZ Therapeutics in the third quarter valued at $107,000. China Universal Asset Management Co. Ltd. purchased a new position in shares of LENZ Therapeutics in the fourth quarter valued at $168,000. Squarepoint Ops LLC acquired a new stake in LENZ Therapeutics during the 2nd quarter valued at $181,000. Finally, MetLife Investment Management LLC purchased a new stake in LENZ Therapeutics during the 3rd quarter worth $182,000. Hedge funds and other institutional investors own 54.32% of the company’s stock.

LENZ Therapeutics Price Performance

Shares of LENZ Therapeutics stock opened at $25.53 on Monday. LENZ Therapeutics has a fifty-two week low of $14.42 and a fifty-two week high of $38.93. The business’s fifty day moving average is $29.49 and its two-hundred day moving average is $26.78.

LENZ Therapeutics (NASDAQ:LENZ) last released its earnings results on Wednesday, November 6th. The company reported ($0.38) earnings per share for the quarter, topping the consensus estimate of ($0.47) by $0.09. During the same period in the previous year, the company earned ($1.33) EPS. As a group, equities analysts expect that LENZ Therapeutics will post -2.18 EPS for the current year.

LENZ Therapeutics Company Profile

LENZ Therapeutics, Inc, a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.